Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ / CD19 depletion or post‐transplant cyclophosphamide
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70004 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Riccardo Masetti und 20 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Cyclophosphamide, Hematopoietic Stem Cell Transplantation, Hematologic Neoplasms, Receptors, Antigen, T-Cell, alpha-beta. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute, Fondazione AIRC per la ricerca sul cancro ETS.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Human leukocyte antigen (HLA)‐haploidentical haematopoietic cell transplantation (haplo‐HCT) is a suitable salvage strategy in children with haematological malignancies experiencing either relapse or graft failure (GF) after the first HCT. Data comparing outcomes of transplant strategies using either TCRαβ/CD19 depletion (TCRαβ) or post‐transplant cyclophosphamide (PTCy) are currently lacking. This retrospective, multicentre study included children with haematological malignancies who received a second haplo‐HCT, in which either TCRαβ depletion or PTCy was used as the graft‐versus‐host disease (GvHD) prophylaxis strategy. Primary outcomes included overall survival (OS), event‐free survival (EFS), cumulative incidence of relapse (CIR) and non‐relapse mortality (NRM). Overall, 123 patients were analysed, 56 receiving PTCy and 67 receiving TCRαβ. Median age at transplant was 9.1 years (range, 1.0–24.7 years). Relapse and GF were the transplant indications in 96 and 27 patients respectively. The 24‐month OS [56.8% (95% CI: 42.5%–71.1%) vs. 43.2% (95% CI: 31.4%–55.1%)] and EFS [44.1% (95% CI: 30.3%–57.8%) vs. 35.8% (95% CI: 24.3%–47.3%)] did not differ between PTCy or TCRαβ cohorts. The CIR [34.0% (95% CI: 23.1%–50.1%) vs. 37.3% (95% CI: 27.3%–50.8%), p = 0.28] and NRM [18.9% (95% CI: 10.7%–33.4%) vs. 25.3% (95% CI: 16.8%–38.2%), p = 0.48] were comparable. Cumulative incidence of 100‐day of any‐grade acute GvHD was higher in the PTCy cohort [55.3% (95% CI: 43.7%–70.4%) vs. 32.8% (95% CI: 23.3%–46.2%), p = 0.02], with non‐statistically significant differences for grade II–IV and grade III–IV. The 24‐month cumulative incidence of chronic GvHD was higher in the PTCy cohort [38.8% (95% CI: 27.6%–54.6%) vs. 11.9% (95% CI: 6.2%–22.8%), p < 0.01], including moderate–severe forms [15.3% (95% CI: 8.1%–29.1%) vs. 1.4% (95% CI: 0.2%–10.4%), p < 0.01]. Infectious complications were comparable except for a higher adenovirus reactivation rate in the TCRαβ group (14.3% vs. 29.9%, p = 0.04). PTCy and TCRαβ offer comparable clinical outcomes in the setting of second haplo‐HCT, although PTCy is associated with a higher incidence of GvHD and lower adenovirus reactivation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Hematology and Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Medical and Surgical Science (DIMEC), University of Bologna, Bologna, Italy.
- Pediatric Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
- Milano-Bicocca University, Monza, Italy.
- Department of Pediatric Oncology/Hematology, Regina Margherita Children's Hospital, Torino, Italy.
- Hematopoietic Stem Cell Transplantation Unit, Department of Pediatric Hematology-Oncology, IRCCS, Istituto Giannina Gaslini, Genoa, Italy.
ORCID-Profile: Davide Leardini, Francesco Baccelli, Maura Faraci, Adriana Balduzzi
Förderung
- Associazione Italiana per la Ricerca sul Cancro
- Ministero della Salute
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Masetti, R., Leardini, D., Gottardi, F., Baccelli, F., Ottaviano, G. A. M., Vendemini, F., Saglio, F., Pierri, F., Algeri, M., Del Bufalo, F., Merli, P., Prete, A., Cesaro, S., Ussowicz, M., Faraci, M., Zecca, M., Fagioli, F., Balduzzi, A., Dalle, J. H., …, & Pagliara, D. (2025). Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ / CD19 depletion or post‐transplant cyclophosphamide. British Journal of Haematology. https://doi.org/10.1111/bjh.70004
Vancouver
Masetti R, Leardini D, Gottardi F, Baccelli F, Ottaviano GAM, Vendemini F, et al. Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ / CD19 depletion or post‐transplant cyclophosphamide. British Journal of Haematology. 2025. doi:10.1111/bjh.70004
BibTeX
@article{Masetti2025,
author = {Masetti, Riccardo and Leardini, Davide and Gottardi, Francesca and Baccelli, Francesco and Ottaviano, Giorgio Antonio Maria and Vendemini, Francesca and Saglio, Francesco and Pierri, Filomena and Algeri, Mattia and Del Bufalo, Francesca and Merli, Pietro and Prete, Arcangelo and Cesaro, Simone and Ussowicz, Marek and Faraci, Maura and Zecca, Marco and Fagioli, Franca and Balduzzi, Adriana and Dalle, Jean-Hugues and Locatelli, Franco and Pagliara, Daria},
title = {Outcomes of children with haematological malignancies given second haploidentical haematopoietic stem cell transplantation with either TCRαβ / CD19 depletion or post‐transplant cyclophosphamide},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70004}
}
EUVIMED